Unfractionated heparin (UFH) is a linear, anionic sulfated glycosaminoglycan with a mean molecular weight (MW) of 15-20 kDa, derived from such tissues as porcine mucosa, rich in mast cells. It is widely used for a number of clinical indications as an effective anticoagulant.
Summary:
The currently available brand-name low-molecularweight heparins (LMWHs) in the United States include dalteparin (Pfizer), enoxaparin (Aventis), and tinzaparin (Pharmion). Other products available, in Europe, include certoparin (Novartis), reviparin (Abbott), nadroparin (GlaxoSmithkline), and parnaparin (Alpha-Wasserman). Each of these LMWHs has a characteristic molecular weight profile and biological activity in terms of an anti-FXa and anti-FIIa potency. The mean molecular weight of these drugs ranges from 4.0 kDa to 7.0 kDa and the anti-FXa:anti-FIIa ratio ranges from 1.5 to 3.5. These agents may also be characterized by the presence of specific chemical end groups such as 2-O-sulfo-4-enepyranosuronic acid at the nonreducing terminus (enoxaparin) or 2,5-anhydro-D-mannose at the reducing terminus (dalteparin). Further, the component oligosaccharide chains exhibit product-specific distribution profiles. It is now widely accepted that individual LMWHs are chemically unique agents and cannot be interchanged therapeutically. Each commercial LMWH has been individually developed for specific clinical indications, which are dose and product dependent. Recently, several generic LMWHs have become available in India (Cutenox and Markaparin) and South America (dilutol, clenox, dripanina), and three companies have filed for regulatory approval of a generic version of enoxaparin in the United States. As the primary aim of a generic drug is to reduce cost without compromising patient care, a generic drug is required to be chemically and biologically equivalent to the pioneer drug. Because LMWHs represent complex natural mucopolysaccharide drugs that have undergone chemical and enzymatic modifications, physicochemical and biological information in addition to molecular weight and anti-FXa:anti-FIIa ratio should be used to determine generic equivalency to the branded drug. We have utilized a previously reported approach to systematically compare three generic versions of enoxaparin obtained from India and Brazil with the branded enoxaparin (Lovenox) available in the United States. Testing included molecular and structural profiling, evaluation in clot-based and amidolytic anti-FXa and anti-FIIa assays, and heparinase-I digestion profiles. While the molecular profiles (4.8 ± 1.8kD) and anticoagulant potencies as determined by activated partial thromboplastin time (APTT) were comparable for all four agents, the generic products showed variations in the thrombin time (TT) and Heptest assays. Two generic and the branded enoxaparin were readily digested by heparinase-I, losing most of their anticoagulant activity, but one generic product resisted digestion. This may have been due to a unique structural feature in this product. These studies show that, while generic LMWHs may exhibit acceptable molecular weight and anti-FXa profiles, they can exhibit assay-based differences and digestion profiles. Testing in animal models to determine safety, efficacy, and pharmacodynamic parameters may be important to verify equivalence. In order to assure that the generic LMWHs are equivalent to branded LMWHs such that equivalent clinical results are obtained, there is a need to develop clear stepwise guidelines that will establish equivalency in terms of physical, chemical, biochemical, pharmacokinetic, and pharmacodynamic properties for these anticoagulant drugs. Key Words: Low molecular weight heparins (LMWHs)-Unfractionated heparin (UFH)-Generic drugs-Pharmacokinetics/ pharmacodynamics (PK/PD).
LMWHs accounts for their benefits over UFH including less protein binding, higher bioavailability, and minimal need for laboratory monitoring (3, 4) .
LMWHs can be produced by using a variety of means of depolymerization (physical, chemical, or enzymatic) of UFH. As shown in Fig. 1 , the means of depolymerization of UFH can cause microstructural differences among different LMWHs. For example, preparation of LMWHs using nitrous acid digestion produces an anhydromanno group at the reducing end of the LMWH chain. LMWHs like dalteparin are produced by this method (5) . Similarly, production of LMWHs by the enzymatic cleavage of UFH with heparinase-I produces a double bond at the reducing end of the resultant LMWH chain (e.g., tinzaparin) (6, 7) . These minor structural differences among different LMWHs may differentiate them in terms of their in vitro profile or their pharmacokinetics/pharmacodynamics behavior (8) . As a result, each of these LMWHs could be identified as a distinct entity.
The currently available LMWHs in the US market include tinzaparin (Innohep), dalteparin (Fragmin), and enoxaparin (Lovenox). Each of these has unique properties and no two LMWHs are alike (9) .
A generic drug is defined as a compound that has physicochemical, biochemical, pharmacologic, and clinical equivalence with its branded version (10) . A generic drug (1) should contain the exact active chemical composition as branded drug; (2) should be identical in dosage, route of administration, and effects as its branded drug; and (3) must exhibit the same bioequivalence and indications as the branded drug.
A generic drug is less expensive than its branded version because the generic manufacturers do not have the investment expenses to develop a generic version of the branded drug. As the patents of the branded drug expire, others can apply for FDA approval to market the generic version of the branded drug. tional patents do not conform to the international (WHO) guidelines. More recently the Canadian health authorities have approved the application of the generic version of enoxaparin marketed by Novomed, a Canadian generic pharmaceutical company. Such an approval is most likely based on the pharmacopoeial description of enoxaparin and may not have taken into consideration some of the issues that have been raised in recent publications (11, 12) . The US FDA has been in discussions with several generic pharmaceutical companies who are interested in introducing generic versions of enoxaparin in the United States. While these discussions are not public, the US FDA does allow the innovator company and the generic companies to express their concerns to the agency in various forms. Such information is available in the form of a public petition submitted on February 19, 2003, and a supplement to this document submitted on February 12, 2004, by Aventis (now Sanofi-Aventis) (13) . On August 20, 2004, Teva Pharmaceuticals responded to this petition and its supplement and asked the US FDA to deny Aventis' petition. As many strong discussions are ongoing concerning the interchangeability of generic LMWHs with branded LMWHs, the question of whether the current regulatory rules for the approval of generics are sufficient remains to be answered.
To investigate the extent of similarities and differences among different generic versions, three generic LMWHs from India and Brazil were compared with a commercially available LMWH from the US market in this study utilizing standardized analytical and biochemical methods.
MATERIALS AND METHODS

Materials
The generic LMWHs included two different batches of LMWHs received from India (Gland Pharma) and an LMWH received from Brazil. These three LMWHs were compared with enoxaparin from the United States. All the drugs were received as white powders at room temperature. Heparinase-I was obtained from IBEX Corp. (Montreal, Canada).
Methods
Molecular weight profiling
The comparative molecular weight (MW) profiling was performed using gel permeation chromatography and high-performance liquid chro-matography (GPC-HPLC). The test agents were prepared at a concentration of 10 mg/mL in 0.3 M sodium sulfate (pH adjusted to 5.0), and 30 µL of each sample was injected into the GPC-HPLC system. A steady flow rate of 0.5 mL/minute of 0.3 M sodium sulfate (mobile phase) was used in the analysis. The run time for each sample was 65 minutes. The GPC-HPLC system was equipped with a controller (Waters 600 Controller) and an autosampler (Waters 717 plus Autosampler), which automatically injects samples in a predefined sequence. Two joint columns (TSK G3000 and TSK G2000 SW) were attached to the ultraviolet detector (Waters 2487 Dual λ Absorbance Detector), which was linked with a refractive index detector (Waters 2414 Refractive Index Detector). The samples were analyzed by using both the UV and RI detectors. The GPC-HPLC system was calibrated by using 19 narrowrange calibrators (NRC) at 205 nm of UV absorption (14) . The analysis of data was performed using the Millennium 32 2000 software.
Enzymatic depolymerization profile by heparinase-I
The neutralization profile of these drugs was carried out after heparinase-I digestion. The extent of purity of the enzyme was screened by using surface enhanced laser desorption ionization (SELDI) technique, a ProteinChip analysis. The LMWHs were prepared at a concentration of 10 mg/mL in 0.3 M sodium sulfate (pH adjusted to 5.0). Then 10 µL of heparinase-I (at stock concentration of 10 U/mL) and 10 µL of 0.1 M calcium chloride were added to 80 µL of each LMWH solution. The drugs with heparinase-I were incubated for 30 minutes at 37°C followed by heat treatment for 3-5 minutes to stop the enzymatic activity. Then 30 µL of each sample was injected into the GPC-HPLC system and the molecular weight profiling was performed as described previously.
Biological profile
The in vitro anticoagulant and antiprotease actions of each generic drug were screened by using standard clot-based assays such as activated partial thromboplastin time (APTT), prothrombin time (PT), thrombin time (5U TT), and Heptest ® . The antifactor Xa and antithrombin (IIa) activities were determined by amidolytic methods. The agents were prepared at concentrations of 1 mg/mL in physiologic saline and supplemented to pooled normal human plasma (NHP) over a concentration range of 100 µg/mL to 0.2 µg/mL. The prepared samples were kept in ice during the entire period of analysis and the tests were performed at 37°C.
Activated partial thromboplastin time assay
In this assay, 100 µL of plasma supplemented with each of these agents was incubated with 100 µL of APTT reagent, platelin (Biomerieux, Durham, NC) at 37°C for five minutes. Following the incubation, 100 µL calcium was added to trigger coagulation. The clotting times were measured using a Fibrometer ® .
Prothrombin time assay
In this assay, 100 µL of plasma supplemented with each of these agents was incubated for 3 minutes at 37°C. Following the incubation, 200 µL of the tissue factor, Thromboplastin C (Dade, Miami, FL) was added to initiate the coagulation. The clotting times were measured using a Fibrometer ® .
Heptest ®
Heptest ® is a clot-based assay used to measure the clotting times after the addition of purified bovine factor Xa. To perform this assay, 100 µL of plasma containing each agent was added to 100 µL of bovine factor Xa (Enzyme Research Laboratory, South Bend, IN) and incubated for 2 minutes at 37°C. Then 100 µL of prewarmed Recalmix ® was added following the incubation and the clotting times were measured using a Fibrometer ® .
Thrombin time assay (5 U) In his assay, 200 µL of plasma supplemented with each of these agents was incubated at 37°C for 3 minutes and 100 µL of thrombin (Enzyme Research Laboratory, South Bend, IN) (5 U/mL) was added after the incubation to trigger the coagulation process. The clotting times were measured by using a Fibrometer ® . The clotting times in the above clotting tests that were >300 seconds were not measured as they are out of the linear range of the assay.
Anti-IIa assay
The antifactor IIa activity of each LMWH was measured by using a chromogenic assay performed on the ACL 300 Plus (Beckman-Coulter, Miami, FL). To perform this assay, 10 µL of each sample supplemented to plasma was incubated for 1 minute at 37°C, followed by an addition of 100 µL of thrombin (10 U/mL). Then 40 µL of Spectrozyme ® TH (American Diagnostica Inc., 
Anti-Xa assay
The anti-Xa effect of these LMWHs was determined by using a chromogenic assay. This assay was performed using the ACL 300 Plus. In this assay, 10 µL of drug sample supplemented to plasma was incubated for 1 minute at 37°C, followed by an addition of 100 µL of bovine factor Xa (Enzyme Research Laboratory, South Bend, IN). Then 75 µL of Spectrozyme ® FXa (American Diagnostica Inc., Stamford, CT) was added. The results are presented as the percent inhibition of the factor IIa calculated with use of the above-cited formula.
RESULTS
Molecular Weight Profile
The comparative molecular profiles of the three generic versions of enoxaparin and lovenox are given in Fig. 2 . The average molecular weights of the LMWHs were determined to be 3905 Da (India 1), 3982 Da (India 2), 4339 Da (Brazil) and 4104 Da (commercial-United States). There was a clear differentiation of distribution of different oligosaccharides such as di, tetra, hexa, octa, etc. in the form of distinct peaks in all three generic versions of enoxaparin. However this differentiation of oligosaccharide distribution was not observed in commercial version of enoxaparin.
Depolymerization by Heparinase-I
The comparative enzymatic depolymerization of these LMWHs by heparinase-I can be seen in Fig. 3 . The two generics from India and the commercial version from the United States were readily digested by heparinase-I. Incubation of these LMWHs with heparinase-I resulted in the cleavage of heparin chains to low MW oligosaccharides with average MWs of 1506 Da (India 1), 1627 Da (India 2) and 1640 Da (commercial-United States). The LMWH chains were cleaved into di, tetra, hexa, and octasaccharides. The pattern of depolymerization was quite similar in all three LMWHs and was superimposable. The elu-tion profile of all three drugs was also similar with the retention times from 38-50 minutes on a time scale (X-axis). However, the generic version from Brazil exhibited a strong resistance towards heparinase-I action. The molecular weight of this compound was reduced to only 3713 Da after heparinase-I digestion (compared to 4339 Da preheparinase-I). Therefore a substantial dissimilarity was observed in the enzymatic depolymerization of these generic versions. 
Biological Profile
Activated partial thromboplastin time assay Fig. 4 depicts the comparative anticoagulant effects of all these drugs in the APTT assay. All the LMWHs exhibited similar effects in this assay. All the drugs had maximum clotting effects (above 300 seconds) at concentrations > 50 µg/mL. A similar concentration dependency of anticoagulation was observed with all the agents.
Prothrombin time assay
Similar to the APTT results, the drugs had comparable anticoagulant effects in the pro- thrombin time assay. As depicted in Fig. 5 , all the drugs exhibited similar concentration-dependent anticoagulant effects with comparable potencies.
Heptest ®
The comparable anticoagulant profile of these four drugs in the Heptest ® assay is shown in Fig.  6 . The two generic versions from India and the commercial version from the United States had similar profiles. The generic LMWH from Brazil exhibited weaker anticoagulant effect at concentrations less than 50 µg/mL but had the maximum effect like the other LMWHs at concentrations greater than 50 µg/mL. Fig. 7 shows the comparative anticoagulant profile of the LMWHs in the thrombin time assay. All four drugs exhibited strong anticoagulant effects in this assay. The maximum inhibitory effects were reached by these drugs at concentrations around 6.2 µg/mL. Similar to the APTT and PT results, the LMWHs exhibited comparable anticoagulant profiles. The two generics from India exhibited relatively stronger effects than commercial-United States and the generic from Brazil. All drugs exhibited similar effects at concentrations greater than 12.5 µg/mL.
Thrombin time assay
Anti-IIa assay
The comparative factor-IIa inhibition by these drugs is shown in Fig. 8 . Two generic versions from India and the commercial version from the United States exhibited similar patterns of inhibition of factor-IIa. These three drugs had similar potencies with IC 50 s of 11.0 µg/mL (India 1), 11.7 µg/mL (United States) and 12.4 µg/mL (India 2). However, the generic version from Brazil was weaker and less potent (IC 50 of 18.7 µg/mL) when compared to the rest.
Anti-Xa assay
The comparable factor Xa inhibition by all these drugs is depicted in Fig. 9 . Two generics from India and the commercial version from the United States had similar effects on the inhibition of factor Xa. All three drugs had similar potencies (IC 50 s ♠1.5 µg/mL). However, the generic from Brazil was weaker and less potent (IC 50 of 3.2 µg/mL) when compared to other generics but had similar efficacy as the other LMWHs at higher concentrations 25 µg/mL.
DISCUSSION
The LMWHs are usually derived from porcine mucosal heparin by use of chemical or enzymat- ic depolymerization methods. These methods result in several structural transformations, which are characteristic of each of the different manufacturing processes. Enoxaparin is manufactured by alkaline hydrolysis benzyl esters of porcine mucosal heparin (15) . This process results in the generation of a double bond at the reducing end of the depolymerized oligosaccharide chains. Recently it has been claimed that this process also results in the generation of an anhydromannose group in up to 25% of the oligosaccharide chains (16, 17) . Thus, the presence of the double bond at one end and the formation of the anhydromannose group are characteristics of this agent.
As several generic versions of this LMWH have become available, structural and molecular characterization showing the similarities not only in the molecular components but also in terms of the presence of a double bond and anhydromannose group are required for the acceptance of a generic version of enoxaparin. While the current studies demonstrated similarities in the molecular profile, the prevalence of the double bond and the anhydromannose content are not known. The molecular weight profile of the three gener-ic versions of enoxaparin exhibited similarities and may be considered acceptable based on the established criteria. In the clotting tests such as the APTT and PT, the three generic versions of enoxaparin were indistinguishable from the commercially available innovator product. However, in the Heptest and thrombin time assays the Brazilian generic version showed a relatively weaker activity. This weaker anticoagulant activity was more obvious in the Heptest assay. This difference may have some influence on the pharmacodynamics of this agent, which can be demonstrated only in the animal models.
In the amidolytic assays to measure anti-Xa and anti-IIa activities, the two products from India and branded enoxaparin exhibited similar anti-Xa and anti-IIa activity. Note that the Brazilian product was also not digested by heparinase-I, in contrast to the two generic versions of enoxaparin from India and the commercial version from the United States. Thus, it may be that the composition of Brazilian heparin differs from the branded product and the two generic products from India.
These studies underscore the importance of performing multiparametric studies using the FIG. 9. Comparative antiprotease effects of different generics and branded enoxaparin in the chromogenic anti-Xa assay. Two generics from India and the commercial version from the United States had similar effects on the inhibition of factor Xa. All three drugs had similar potencies. However, the generic from Brazil was weaker and less potent when compared to other generics but had efficacy similar to that of the other LMWHs at higher concentrations greater than 25 µg/mL. currently available methods for the in vitro evaluation of LMWHs. While differences in biological assays may be noted, the anticoagulant and antithrombotic efficacy in animal models along with the PK/PD profile may be necessary to demonstrate the bioequivalence of generic versions of LMWHs. The molecular profile and biological activities of the generic versions can be adjusted to mimic the innovator product. However, these adjustments may not be sufficient for bioequivalence. The currently available guidelines for validating the molecular and biological profile of LMWHs may not be adequate in establishing acceptance criteria for LMWHs. Thus, additional tests such as thrombin generation inhibition, relative neutralization profile, and demonstration of antithrombotic activity in animal models should be considered.
The differentiation of LMWHs has significant clinical implications because enoxaparin represents a LMWH with wide usage for arterial, venous, and cardiovascular disorders. As the dosage range varies widely for different indications, minor compositional differences may impact pharmacokinetics/pharmacodynamics of these agents. Therefore, the generic versions of enoxaparin must exhibit all physicochemical and biological attributes to mimic the clinical performance of the innovator product. Some of the ongoing issues related to the development of generic versions of LMWHs were discussed in a recent editorial (12) .
It is clear from the ongoing dilemmas that heparin represents a polycomponent, polypharmacologic mixture of sulfated mucopolysaccharide, which is difficult to characterize. The LMWHs represent depolymerized heparins with processdependent, chemical, and physical modifications. Thus, each LMWH is different from the other. This may also be true for the generic products, and chemical equivalence alone may not be sufficient to prove the sameness of the agents. More importantly, pharmacodynamic characterization and clinical equivalence should be required as acceptance criteria for the generic LMWHs.
